Table 4.
Subgroup analysis for progression-free survival, overall survival, and objective response rate.
| Group | PFS | OS | ORR | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | HR (95% CI) | P | I2 (%) | No. of studies | HR (95% CI) | P | I2 (%) | No. of studies | RR (95% CI) | P | I2 (%) | |
| Total | 8 | 0.81 [0.66, 0.99] | 0.04 | 0 | 6 | 1.00 [0.95, 1.05] | 0.97 | 0 | 5 | 0.91 [0.64, 1.29] | 0.58 | 20 |
| Nation | ||||||||||||
| East Asia | 5 | 0.75 [0.58, 0.98] | 0.03 | 20 | 3 | 1.02 [0.69, 1.50] | 0.93 | 0 | 4 | 0.92 [0.63, 1.34] | 0.65 | 39 |
| Egypt | 1 | 0.96 [0.51, 1.82] | 0.90 | NA | 1 | 1.00 [0.87, 1.15] | 1 | NA | 1 | 0.83 [0.30, 2.31] | 0.73 | NA |
| Canada | 1 | 0.84 [0.41, 1.74] | 0.64 | NA | 1 | 0.63 [0.26, 1.50] | 0.3 | NA | NA | NA | NA | NA |
| Italy | 1 | 0.89 [0.57, 1.40] | 0.61 | NA | 1 | 1.09 [0.44, 2.68] | 0.85 | NA | NA | NA | NA | NA |
| Treatment line | ||||||||||||
| First line | 4 | 0.76 [0.58, 1.00] | 0.05 | 0.37 | 3 | 0.96 [0.61, 1.51] | 0.87 | 0 | 2 | 0.57 [0.31, 1.02] | 0.06 | 0 |
| First and second line | 1 | 0.84 [0.41, 1.74] | 0.64 | NA | 1 | 0.63 [0.26, 1.50] | 0.30 | NA | NA | NA | NA | NA |
| Unclear | 3 | 0.87 [0.63, 1.22] | 0.43 | 0 | 2 | 1.00 [0.95, 1.05] | 0.97 | 0 | 3 | 1.20 [0.77, 1.89] | 0.42 | 0 |
| Initial dosage | ||||||||||||
| 50 mg/d | 5 | 0.76 [0.59, 0.97] | 0.03 | 0 | 4 | 1.00 [0.95, 1.05] | 0.99 | 0 | 3 | 1.20 [0.77, 1.89] | 0.42 | 0 |
| 50/37.5/25 mg/d | 1 | 0.54 [0.21, 1.38] | 0.20 | NA | NA | NA | NA | NA | 1 | 0.62 [0.30, 1.25] | 0.18 | NA |
| Unclear | 2 | 0.99 [0.68, 1.43] | 0.94 | 0 | 2 | 0.93 [0.54, 1.63] | 0.81 | 0 | 1 | 0.50 [0.18, 1.40] | 0.19 | NA |
| Study qualitya | ||||||||||||
| High quality | 5 | 0.80 [0.64, 1.01] | 0.06 | 16 | 4 | 1.03 [0.72, 1.47] | 0.87 | 0 | 3 | 1.05 [0.67, 1.64] | 0.83 | 35 |
| Medium quality | 3 | 0.81 [0.53, 1.25] | 0.35 | 0 | 2 | 1.00 [0.95, 1.05] | 0.95 | 7 | 2 | 0.69 [0.38, 1.24] | 0.21 | 0 |
| Study design | ||||||||||||
| RCT | 1 | 0.75 [0.44, 1.27] | 0.29 | NA | 1 | 1.15 [0.64, 2.05] | 0.64 | NA | 1 | 1.42 [0.80, 2.51] | 0.23 | NA |
| RS | 7 | 0.82 [0.65, 1.02] | 0.07 | 0 | 5 | 1.00 [0.95, 1.05] | 0.94 | 0 | 4 | 0.71 [0.45, 1.12] | 0.14 | 0 |
PFS, progression-free survival; OS, overall survival; ORR, objective response rate; HR, hazard ratio; RR, risk ratio; CI, confidence interval; NA, not available.
a
Study quality was evaluated using the Newcastle-Ottawa Scale for retrospective observational studies and the Jadad scale for randomized controlled trials.